M2/M1 ratio of tumor associated macrophages and PPAR-gamma expression in uveal melanomas with class 1 and class 2 molecular profiles

Experimental Eye Research

Volumn 107, Issue , 2013, Pages 52-58

  Herwig, Martina C ^a,b   Bergstrom, Chris ^a   Wells, Jill R ^a   Höller, Tobias ^b   Grossniklaus, Hans E ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Macrophage polarization; Macrophages; PPAR gamma; Uveal melanoma

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CELL PROLIFERATION; CLINICAL ARTICLE; CYTOPLASM; FEMALE; GENE EXPRESSION; HISTOLOGY; HUMAN; MALE; MOLECULAR DYNAMICS; PHENOTYPE; POLARIZATION; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; UVEA MELANOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MACROPHAGES; MALE; MELANOMA; MIDDLE AGED; PPAR GAMMA; RECEPTORS, CELL SURFACE; RNA, NEOPLASM; UVEAL NEOPLASMS; VON WILLEBRAND FACTOR; YOUNG ADULT;

EID: 84871661615     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2012.11.012     Document Type: Article

References (33)

1. Affeldt J.C., Minckler D.S., Azen S.P., Yeh L. Prognosis in uveal melanoma with extrascleral extension. Arch. Ophthalmol. 1980, 98:1975-1979.
2. Amato A.A., de Assis Rocha Neves F. Idealized PPARγ-based therapies: lessons from bench and bedside. PPAR Res. 2012, 2012. 978687.
3. Bhatia B., Potts C.R., Guldal C., Choi S., Korshunov A., Pfister S., Kenney A.M., Nahle Z.A. Hedgehog-mediated regulation of PPARγ controls metabolic patterns in neural precursors and shh-driven medulloblastoma. Acta Neuropathol. 2012, 123:587-600.
4. Bronkhorst I.H., Ly L.V., Jordanova E.S., Vrolijk J., Versluis M., Luyten G.P., Jager M.J. Detection of M2-macrophages in uveal melanoma and relation with survival. Investig. Ophthalmol. Vis. Sci. 2011, 52:643-650.
5. Bronkhorst I.H., Vu T.H., Jordanova E.S., Luyten G.P., Burg S.H., Jager M.J. Different subsets of tumor-infiltrating lymphocytes correlate with macrophage influx and monosomy 3 in uveal melanoma. Investig. Ophthalmol. Vis. Sci. 2012, 53:5370-5378.
6. Burgermeister E., Seger R. MAPK kinases as nucleo-cytoplasmic shuttles for PPARgamma. Cell Cycle 2007, 6:1539-1548.
7. Cao X., Shen D., Patel M.M., Tuo J., Johnson T.M., Olsen T.W., Chan C.C. Macrophage polarization in the maculae of age-related macular degeneration: a pilot study. Pathol. Int. 2011, 61:528-535.
8. de la Cruz P.O., Specht C.S., McLean I.W. Lymphocytic infiltration in uveal malignant melanoma. Cancer 1990, 65:112-115.
9. de Waard-Siebinga I., Hilders C.G., Hansen B.E., van Delft J.L., Jager M.J. HLA expression and tumor-infiltrating immune cells in uveal melanoma. Graefes Arch. Clin. Exp. Ophthalmol. 1996, 234:34-42.
10. Foss A.J., Alexander R.A., Jefferies L.W., Hungerford J.L., Harris A.L., Lightman S. Microvessel count predicts survival in uveal melanoma. Cancer Res. 1996, 56:2900-2903.
11. Freudlsperger C., Moll I., Schumacher U., Thies A. Anti-proliferative effect of peroxisome proliferator-activated receptor gamma agonists on human malignant melanoma cells in vitro. Anticancer Drugs 2006, 17:325-332.
12. Fujisaka S., Usui I., Bukhari A., Ikutani M., Oya T., Kanatani Y., Tsuneyama K., Nagai Y., Takatsu K., Urakaze M., Kobayashi M., Tobe K. Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice. Diabetes 2009, 58:2574-2582.
13. Giaginis C., Politi E., Alexandrou P., Sfiniadakis J., Kouraklis G., Theocharis S. Expression of peroxisome proliferator activated receptor-gamma (PPAR-gamma) in human non-small cell lung carcinoma: correlation with clinicopathological parameters, proliferation and apoptosis related molecules and patients' survival. Pathol. Oncol. Res. 2012.
14. Gooden M.J., de Bock G.H., Leffers N., Daemen T., Nijman H.W. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br. J. Cancer 2011, 105:93-103.
15. Harbour J.W. The genetics of uveal melanoma: an emerging framework for targeted therapy. Pigment Cell Melanoma Res. 2012, 25:171-181.
16. Hirsch J., Johnson C.L., Nelius T., Kennedy R., Riese W., Filleur S. PEDF inhibits IL8 production in prostate cancer cells through PEDF receptor/phospholipase A2 and regulation of NFκB and PPARγ. Cytokine 2011, 55:202-210.
17. Ho T.C., Yang Y.C., Chen S.L., Kuo P.C., Sytwu H.K., Cheng H.C., Tsao Y.P. Pigment epithelium-derived factor induces THP-1 macrophage apoptosis and necrosis by the induction of the peroxisome proliferator-activated receptor gamma. Mol. Immunol. 2008, 45:898-909.
18. Jager M.J., Ly L.V., El Filali M., Madigan M.C. Macrophages in uveal melanoma and in experimental ocular tumor models: friends or foes?. Prog. Retin. Eye Res. 2011, 30:129-146.
19. Kim H.H., Kim Y.S., Kang Y.K., Moon J.S. Leptin and peroxisome proliferator-activated receptor gamma expression in colorectal adenoma. World J. Gastroenterol. 2012, 18:557-562.
20. Knapp P., Chabowski A., Blachnio-Zabielska A., Jarzabek K., Wolczynski S. Altered peroxisome-proliferator activated receptors expression in human endometrial cancer. PPAR Res. 2012, 2012. 471524.
21. Kulkarni A.A., Woeller C.F., Thatcher T.H., Ramon S., Phipps R.P., Sime P.J. Emerging PPARγ-independent role of PPARγ ligands in lung diseases. PPAR Res. 2012, 2012. 705352.
22. Lee C., Ramirez J.A., Guitart J., Diaz L.K. Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma during malignant melanoma progression. J. Cutan. Pathol. 2008, 35:989-994.
23. Ly L.V., Baghat A., Versluis M., Jordanova E.S., Luyten G.P., van Rooijen N., van Hall T., van der Velden P.A., Jager M.J. In aged mice, outgrowth of intraocular melanoma depends on proangiogenic M2-type macrophages. J. Immunol. 2010, 185:3481-3488.
24. Maat W., Ly L.V., Jordanova E.S., de Wolff-Rouendaal D., Schalij-Delfos N.E., Jager M.J. Monosomy of chromosome 3 and an inflammatory phenotype occur together in uveal melanoma. Investig. Ophthalmol. Vis. Sci. 2008, 49:505-510.
25. Makitie T., Summanen P., Tarkkanen A., Kivela T. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Investig. Ophthalmol. Vis. Sci. 2001, 42:1414-1421.
26. Mantovani A., Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr. Opin. Immunol. 2010, 22:231-237.
27. McLean I.W., Saraiva V.S., Burnier M.N. Pathological and prognostic features of uveal melanomas. Can. J. Ophthalmol. 2004, 39:343-350.
28. Meyer S., Vogt T., Landthaler M., Berand A., Reichle A., Bataille F., Marx A.H., Menz A., Hartmann A., Kunz-Schughart L.A., Wild P.J. Cyclooxygenase 2 (COX2) and peroxisome proliferator-activated receptor gamma (PPARG) are stage-dependent prognostic markers of malignant melanoma. PPAR Res. 2009, 2009. 848645.
29. Nemenoff R. Activation of PPARγ in myeloid cells promotes lung cancer progression and metastasis. Oncoimmunology 2012, 1:403-404.
30. Onken M.D., Worley L.A., Ehlers J.P., Harbour J.W. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 2004, 64:7205-7209.
31. Papadaki I., Mylona E., Giannopoulou I., Markaki S., Keramopoulos A., Nakopoulou L. PPARgamma expression in breast cancer: clinical value and correlation with ERbeta. Histopathology 2005, 46:37-42.
32. Yang H., Grossniklaus H.E. Constitutive overexpression of pigment epithelium-derived factor inhibition of ocular melanoma growth and metastasis. Investig. Ophthalmol. Vis. Sci. 2010, 51:28-34.
33. Zuidervaart W., van Nieuwpoort F., Stark M., Dijkman R., Packer L., Borgstein A.M., Pavey S., van der Velden P., Out C., Jager M.J., Hayward N.K., Gruis N.A. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br. J. Cancer 2005, 92:2032-2038.